VISIOPHARM A/S: Financial statements 2012
CVR: 26186676
Source: annual report 2012, Danish Business Authority
01/10/2011 – 30/09/2012
VISIOPHARM A/S (CVR 26186676) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK 7,334,504 and a net result of DKK -958,323. Equity in the 2012 report amounted to DKK 5,477,927. The solvency ratio was 59.5%.
- Gross Profit
- DKK 7,334,504
- Profit/Loss
- DKK -958,323
- Equity
- DKK 5,477,927
- Total Assets
- DKK 9,209,145
Official annual report
Keep an eye on VISIOPHARM A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of December 28, 2012, Henrik Stender has joined the board of directors of VISIOPHARM A/S.
As of December 28, 2012, Martin Bonde has left the board of directors of VISIOPHARM A/S.
As of May 25, 2012, Niels Tækker Foged has stepped down as director of VISIOPHARM A/S.
As of February 21, 2012, Johan Doré Hansen has joined the board of directors of VISIOPHARM A/S.
As of February 21, 2012, Niels Tækker Foged has left the board of directors of VISIOPHARM A/S.
About VISIOPHARM A/S
VISIOPHARM A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2001. The company is registered under the industry Computerkonsulentbistand og forvaltning af computerfaciliteter. The company was previously named VISIOPHARM ApS. The management consists of Johan Doré Hansen and Michael Grunkin. The board consists of Evis Hursever (chair), Andrew James Thomson and Per Fredrik Thorell. The company is owned by Neptune Denmark Holdco ApS. The company has 54 employees (2026). In 2025, the company reported revenue of DKK 130,617,000 and a net result of DKK -17,223,000 compared with DKK -17,363,000 the year before. Equity in the 2025 report amounted to DKK -4,949,000.